Aerosol Medication Use in COVID-19 Pandemic
Asthma Allergy Immunology
; 18(2):110-112, 2020.
Artículo
en Inglés
| EMBASE | ID: covidwho-2319930
ABSTRACT
Administration of aerolized drugs to patients diagnosed with COVID-19 leads to the risk of transmission of patient-generated infectious aerosols to healthcare providers.While the COVID-19 pandemic is ongoing, in order to provide the best treatment for patients and at the same time to protect healthcare providers at the highest level, it is necessary to increase access to information and pay maximum attention to preventive measures.Copyright © 2020 Bilimsel Tip Yayinevi. All rights reserved.
Aerosolized medications; Bioaerosols; covid-19; access to information; aerosol; ambient air; article; artificial ventilation; assisted ventilation; asthma/dt [Drug Therapy]; attention; coronavirus disease 2019; drug delivery system; expired air; health care personnel; high flow nasal cannula therapy; human; invasive ventilation; noninvasive ventilation; oxygen therapy; pandemic; respiratory failure; ventilated patient; ventilator associated pneumonia; virus transmission; bronchodilating agent/ad [Drug Administration]; bronchodilating agent/dt [Drug Therapy]; bronchodilating agent/ih [Inhalational Drug Administration]; corticosteroid/ad [Drug Administration]; corticosteroid/dt [Drug Therapy]; corticosteroid/ih [Inhalational Drug Administration]; expiratory valve; face mask; HEPA filter; metered dose inhaler; nebulizer; surgical mask; ventilator
Texto completo:
Disponible
Colección:
Bases de datos de organismos internacionales
Base de datos:
EMBASE
Idioma:
Inglés
Revista:
Asthma Allergy Immunology
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS